Explain this page
Arphra AIPlain-English read on Cocrystal Pharma, Inc.’s valuationNo recent stories.
today
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Candlestick · 1Y
Open in chart workstation →COCP
0.99+1.53%H 2.03L 0.86MA50 1.14MA200 —Avg vol 2.1M
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.43% | +0.49% | -13.48% | -8.72% | +0.51% | +1.63% | -33.22% | -59.72% | -93.57% | -99.50% | -99.89% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$0.99
Bid
$0.95
4,066 sh
Ask
$1.02
1,000 sh
Spread
$0.070
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officerglobenewswire.com·Jun 03, 2026
- Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officerglobenewswire.com·Jun 03, 2026
Peers
No peer list available for COCP.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|